HC Wainwright Upgrades Lipocine (NASDAQ:LPCN) to “Strong-Buy”
Lipocine (NASDAQ:LPCN – Get Free Report) was upgraded by research analysts at HC Wainwright to a “strong-buy” rating in a research report issued on Thursday, Marketbeat reports. The brokerage presently has a $8.00 price target on the specialty pharmaceutical company’s stock. HC Wainwright’s target price would suggest a potential upside of 138.10% from the stock’s […]
Lipocine (NASDAQ:LPCN – Get Free Report) was upgraded by research analysts at HC Wainwright to a “strong-buy” rating in a research report issued on Thursday, Marketbeat reports. The brokerage presently has a $8.00 price target on the specialty pharmaceutical company’s stock. HC Wainwright’s target price would suggest a potential upside of 138.10% from the stock’s […]
